– USA, NY – Firefly Neuroscience, Inc. (NASDAQ: AIFF), an Artificial Intelligence company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders, announced the appointment of current Board director Greg Lipschitz as Executive Chairman, effective as of December 3, 2024, succeeding David Johnson who resigned from the board and stepped down as Executive Chairman position, effective as of November 30, 2024.
About Greg Lipschitz
Greg Lipschitz has served as Firefly’s director since December 2022. He has over 13 years of combined experience in private equity, merchant banking, capital markets, and finance. From June 2018 to February 2024, Greg Lipschitz served as VP of Lazer Capital. He serves as MD of Old Stone Advisors, a financial advisory firm. Greg Lipschitz has advised on over $1 billion of transactions.
Greg Lipschitz is a Chartered Financial Analyst and received his bachelor’s degree in business from the Richard Ivey Business School at the University of Western Ontario.
About Firefly
Firefly is an Artificial Intelligence company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders. Firefly’s FDA-510(k) cleared Brain Network Analytics technology revolutionizes diagnostic and treatment monitoring methods for conditions such as depression, dementia, anxiety disorders, concussions, and ADHD. Over the past 15 years, Firefly has built a comprehensive database of brain wave tests, securing patent protection, and achieving FDA clearance. The Company is now launching BNA commercially, targeting pharmaceutical companies engaged in drug research and clinical trials, as well as medical practitioners for clinical use.
Brain Network Analytics was developed using artificial intelligence and machine learning on Firefly’s extensive proprietary database of standardized, high-definition longitudinal electroencephalograms of over 17,000 patients representing twelve disorders, as well as clinically normal patients. BNA, in conjunction with an FDA-cleared EEG system, can provide clinicians with comprehensive insights into brain function. These insights can enhance a clinician’s ability to accurately diagnose mental and cognitive disorders and to evaluate what therapy and/or drug is best suited to optimize a patient’s outcome.
For more information: https://fireflyneuro.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.